Cargando…

Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator

Hypertrophic cardiomyopathy (HCM) is a genetic disease associated with a risk of malignant ventricular tachyarrhythmias and sudden cardiac death (SCD). Assessment of the SCD risk is crucial for its clinical management, and there has been considerable interest in developing risk stratification strate...

Descripción completa

Detalles Bibliográficos
Autor principal:	Park, Yae Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Internal Medicine 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816680/ https://www.ncbi.nlm.nih.gov/pubmed/36353786 http://dx.doi.org/10.3904/kjim.2022.144

Ejemplares similares

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy
por: Sanchez, Diego Jimenez, et al.
Publicado: (2018)

Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy
por: Ghosh, Joydeep, et al.
Publicado: (2005)

CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter–Defibrillator in Non-Ischemic Cardiomyopathy
por: Keil, Laura, et al.
Publicado: (2021)

Performance of the PRIMaCY sudden death risk prediction model for childhood hypertrophic cardiomyopathy: implications for implantable cardioverter-defibrillator decision-making
por: Norrish, Gabrielle, et al.
Publicado: (2023)

Implantable cardioverter-defibrillator prevents sudden death in patients with Chagas cardiomyopathy in the Brazilian Amazon
por: Couceiro, Katia do Nascimento, et al.
Publicado: (2021)

Sudden Cardiac Death Risk over Time in HCM Patients with Implantable Cardioverter-Defibrillator
por: Klopotowski, Mariusz, et al.
Publicado: (2022)

Subcutaneous implantable cardioverter-defibrillator (S-ICD) for secondary prevention of sudden cardiac death
por: Kempa, Maciej, et al.
Publicado: (2016)

Implantable Cardioverter‐Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review
por: Borne, Ryan T., et al.
Publicado: (2017)

Use of Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in Asia
por: Ueda, Nobuhiko, et al.
Publicado: (2023)

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience
por: Weinstock, Jonathan, et al.
Publicado: (2016)

Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
por: Goldstein, Sarah A., et al.
Publicado: (2023)

Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death
por: Wäßnig, Nadine K., et al.
Publicado: (2016)

Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death
por: Kutyifa, Valentina, et al.
Publicado: (2018)

Sudden Cardiac Death in Children Affected by Cardiomyopathies: An Update on Risk Factors and Indications at Transvenous or Subcutaneous Implantable Defibrillators
por: Rella, Valeria, et al.
Publicado: (2020)

Predictors of appropriate therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death
por: Ahmed, Imdad, et al.
Publicado: (2010)

Ventricular tachycardia prediction in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death
por: Lebedeva, Viktoria K., et al.
Publicado: (2018)

Subcutaneous Implantable Cardioverter Defibrillators for the Prevention of Sudden Cardiac Death: Pediatric Single-Center Experience
por: Wieniawski, Piotr, et al.
Publicado: (2022)

Underutilization of Implantable Cardioverter Defibrillator in Primary Prevention of Sudden Cardiac Arrest
por: Lakshmanadoss, Umashankar, et al.
Publicado: (2011)

Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator
por: Skowasch, Dirk, et al.
Publicado: (2018)

Anesthesia in a Child with Newly Diagnosed Hypertrophic Cardiomyopathy for Placement of Implantable Cardioverter Defibrillator
por: Kumar, Rajnish, et al.
Publicado: (2018)

Risk factors of sudden cardiac death in hypertrophic cardiomyopathy
por: Hong, Ying, et al.
Publicado: (2022)

Personalized Management of Sudden Death Risk in Primary Cardiomyopathies: From Clinical Evaluation and Multimodality Imaging to Ablation and Cardioverter-Defibrillator Implant
por: Lazzeroni, Davide, et al.
Publicado: (2023)

Effects and Complications of Subcutaneous Implantable Cardioverter-Defibrillator in the Prevention of Sudden Cardiac Death: A Narrative Review
por: Pagore, Prasad A, et al.
Publicado: (2022)

Implantable cardioverter-defibrillator implantation should be considered in high-risk patients with apical hypertrophic cardiomyopathy as the same manner with the septal type
por: Park, Y M, et al.
Publicado: (2023)

Wearable Cardioverter-defibrillators for the Prevention of Sudden Cardiac Death: A Meta-analysis
por: Nguyen, Elaine, et al.
Publicado: (2018)

Hypertrophic cardiomyopathy: Sudden cardiac death risk stratification in adults
por: Jordà, Paloma, et al.
Publicado: (2018)

High-Risk Apical Hypertrophic Cardiomyopathy Requiring an Implantable Cardioverter-Defibrillator: A Case Report of an Overlooked Etiology
por: Rathore, Azeem, et al.
Publicado: (2023)

Impact of Cardiac Magnetic Resonance (CMR) on utilization of Implantable-Cardioverter-Defibrillators (ICD) for primary prophylaxis of sudden cardiac death
por: Ertel, Andrew, et al.
Publicado: (2013)

Arrhythmic Sudden Cardiac Death and the Role of Implantable Cardioverter-Defibrillator in Patients with Cardiac Amyloidosis—A Narrative Literature Review
por: Liżewska-Springer, Aleksandra, et al.
Publicado: (2021)

Under-Utilization of Implantable Cardioverter Defibrillators in Patients with Heart Failure - The Current State of Sudden Cardiac Death Prophylaxis
por: Pillarisetti, Jayasree, et al.
Publicado: (2016)

Optimal Medications and Appropriate Implantable Cardioverter-defibrillator Shocks in Aborted Sudden Cardiac Death Due to Coronary Spasm
por: Sueda, Shozo, et al.
Publicado: (2018)

Efficacy of Implantable Cardioverter-defibrillators for Secondary Prevention of Sudden Cardiac Death in Patients with End-stage Renal Disease
por: Payne, Taylor, et al.
Publicado: (2020)

Single‐ Versus Dual‐Chamber Implantable Cardioverter‐Defibrillator for Primary Prevention of Sudden Cardiac Death in the United States
por: Margolis, Gilad, et al.
Publicado: (2023)

Higher defibrillation threshold in methamphetamine cardiomyopathy patients with implantable cardioverter-defibrillator
por: Malhotra, Rakesh, et al.
Publicado: (2017)

Prevention of sudden cardiac death by the wearable cardioverter defibrillator in a young patient with cardiac sarcoidosis
por: Andrié, René, et al.
Publicado: (2017)

Living with hypertrophic cardiomyopathy and an implantable defibrillator
por: Magnusson, Peter, et al.
Publicado: (2017)

Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator?
por: Israel, Carsten, et al.
Publicado: (2022)

Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention
por: Yazaki, Kyoichiro, et al.
Publicado: (2021)

Defying the Odds of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
por: Rostomian, Ara H., et al.
Publicado: (2020)

Characteristics of Cardiac Memory in Patients with Implanted Cardioverter-defibrillators: The Cardiac Memory with Implantable Cardioverter-defibrillator (CAMI) Study
por: Haq, Kazi T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jfij7g2vf07iciba1t5om0f9td